We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

55 hedge funds and large institutions have $17M invested in Oramed Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

320% more call options, than puts

Call options by funds: $21K | Put options by funds: $5K

11% more capital invested

Capital invested by funds: $15.2M → $17M (+$1.73M)

2.47% more ownership

Funds ownership: 14.6% → 17.07% (+2.5%)

7% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 14

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

7% less funds holding

Funds holding: 59 → 55 (-4)

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

Holders
55
Holders Change
-4
Holders Change %
-6.78%
% of All Funds
0.79%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
7
Increased
15
Reduced
14
Closed
11
Calls
$21K
Puts
$5K
Net Calls
+$16K
Net Calls Change
-$28K

Top Buyers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
+$2.04M
2
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$272K
3
Millennium Management
Millennium Management
New York
+$66.3K
4
Marshall Wace
Marshall Wace
United Kingdom
+$54.9K
5
Citadel Advisors
Citadel Advisors
Florida
+$52.2K

Top Sellers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$99.1K
2
OAM
Oxford Asset Management
United Kingdom
-$25.9K
3
Group One Trading
Group One Trading
Illinois
-$22.2K
4
Two Sigma Investments
Two Sigma Investments
New York
-$21.2K
5
JP Morgan Chase
JP Morgan Chase
New York
-$17.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
American Century Companies
26
American Century Companies
Missouri
$47.8K – – –
SAI
27
Savvy Advisors Inc
New York
$45.9K – – –
AI
28
Atria Investments
North Carolina
$43.9K +$3.4K +1,393 +8%
SCM
29
Sage Capital Management
New Jersey
$40.9K – – –
PCM
30
Prelude Capital Management
New York
$35.2K +$35.2K +14,435 New
Barclays
31
Barclays
United Kingdom
$32.3K – – –
Assenagon Asset Management
32
Assenagon Asset Management
Luxembourg
$32K -$8.05K -3,301 -20%
NEWAS
33
N.E.W. Advisory Services
Wisconsin
$30.2K – – –
VF
34
Virtu Financial
New York
$30K -$6.47K -2,653 -18%
JSW
35
Journey Strategic Wealth
New Jersey
$30K +$3.12K +1,278 +12%
AS
36
Altshuler Shaham
Israel
$29.4K – – –
CAM
37
Close Asset Management
United Kingdom
$28K – – –
Wealth Enhancement Advisory Services
38
Wealth Enhancement Advisory Services
Minnesota
$27.6K -$244 -100 -0.9%
Mariner
39
Mariner
Kansas
$25.7K – – –
GJIA
40
Glass Jacobson Investment Advisors
Maryland
$25.7K – – –
SPIA
41
Steward Partners Investment Advisory
New York
$21.5K – – –
TRCT
42
Tower Research Capital (TRC)
New York
$19.5K -$10.7K -4,392 -35%
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
$10K -$2.08K -854 -17%
Osaic Holdings
44
Osaic Holdings
Arizona
$9.39K – – –
Northwestern Mutual Wealth Management
45
Northwestern Mutual Wealth Management
Wisconsin
$3.84K – – –
Fidelity Investments
46
Fidelity Investments
Massachusetts
$3.66K +$3.66K +1,500 New
CHC
47
City Holding Co
West Virginia
$2.61K – – –
ME
48
McIlrath & Eck
Washington
$2.44K -$2.44K -1,000 -50%
CFGS
49
Concourse Financial Group Securities
Alabama
$2.44K – – –
NA
50
Nordwand Advisors
Pennsylvania
$2.44K +$2.44K +1,000 New
1
2
3

ORMP Hedge Fund Activity: Q3 2024 in Review

55 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2024, worth a combined $17M — up 11% from $15.2M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ORMP and 7 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 15 added.

The largest buyer was BML Capital Management, adding an estimated $2.04M. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $99.1K sold.

  • 55 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2024, down from 59 in Q2 2024.
  • Funds reported $17M of Oramed Pharmaceuticals stock for Q3 2024, up 11% quarter-over-quarter.
  • 7 funds opened new Oramed Pharmaceuticals positions in Q3 2024 and 11 closed out, a net change of -4 holders.
  • The largest Oramed Pharmaceuticals buyer in Q3 2024 was BML Capital Management, an estimated $2.04M added.
  • The largest Oramed Pharmaceuticals seller in Q3 2024 was D.E. Shaw & Co, an estimated $99.1K sold.

Based on aggregated 13F filings for Q3 2024.